COM701 Phase 1 data presented at ESMO 2025 characterized patients who derived clinical benefit and informed the design of the ongoing MAIA-ovarian platform trial Enrolling patients in the U.S., Israel and France in the MAIA-ovarian platform trial evaluating COM701 maintenance therapy in patients with platinum sensitive ovarian cancer with interim analysis now estimated in Q1 2027 SITC 2025 – Compugen presented Phase 1 trial... Read More

HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on January 4, 2024 , it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance... Read More

Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will be eligible to receive a milestone payment of $10 million from... Read More

Conference call today, December 19, 2023 , 8:30 AM ET to discuss the license agreement HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will host a conference call at 8:30 AM ET today, to discuss the exclusive license agreement with Gilead announced today, for the... Read More

COM701 + nivolumab + BMS-986207 (anti-TIGIT) resulted in clinically meaningful durable partial responses > 16 months in platinum resistant ovarian cancer patients COM701 dual and triple combinations mediated clinical benefit in platinum resistant ovarian cancer patients, independent of baseline inflammatory status and was associated with an increase in T cell infiltration to the tumor Metastatic breast cancer adds to... Read More

HOLON, Israel , Nov. 3, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on November 3, 2023 , it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that its ordinary shares failed to maintain a minimum bid... Read More

COM503, a potential first-in-class, high affinity anti-IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Anti-IL-18BP antibody immune modulation is confined to the tumor site expected to have a favorable therapeutic window compared to engineered cytokines Data to be presented in an oral presentation at SITC, 2023 HOLON, Israel , Oct. 31, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN)... Read More

HOLON, Israel , Oct. 24, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023 , before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a... Read More

HOLON, Israel , Oct. 3, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, it will present innovative single-cell approaches and high resolution single cell spatial transcriptomics data at the Single Cell Genomics 2023 meeting taking place between 9-11 October 2023 , Engelberg, Switzerland . The data... Read More

HOLON, Israel , Oct. 2 , 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Japanese Patent Office has granted Compugen a patent for treating cancer with a triple combination of any anti- PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody. Japanese patent No. JP7348072B2 , titled "Triple... Read More

HOLON, Israel , Aug. 31, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will be available on demand on the Investor Relations section of Compugen's website at www.cgen.com from... Read More

Advancing enrollment in two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal cancer and platinum resistant ovarian cancer; initial findings expected by year end Data from multiple studies planned to be presented by the end of the year: - New data from metastatic breast cancer study evaluating COM701+ nivolumab - New translational data and initial biomarker... Read More

Patent EP3258951B1 , Anti-PVRIG Antibodies and Methods of Use, granted by the European Patent Office covers any anti-PVRIG antibody which activates T cells and/or NK cells for use in the treatment of cancer The opposition division of the European Patent Office ruled to maintain the broad claims of the patent as granted HOLON, Israel , July 17, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage... Read More

Study builds on clinical benefit reported in heavily pretreated platinum resistant ovarian cancer patients treated with dual and triple combination of COM701 + nivolumab ± BMS-986207 Initial findings expected by the end of 2023 HOLON, ISRAEL , June 22, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced... Read More

HOLON, Israel , June 13, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on June 12, 2023 , it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with... Read More

COM701 in combination with nivolumab and BMS-986207 (anti-TIGIT) resulted in encouraging confirmed durable partial responses (overall response rate 22% (2/9) and disease control rate 44%) with a favorable safety profile Partial response reported in a patient on study treatment for almost 7 months who was previously refractory to standard of care lenvatinib and pembrolizumab Greater peripheral immune activation seen in... Read More

On track to deliver initial findings from studies with the triple blockade of PVRIG, TIGIT and PD-1 in patients with MSS CRC and platinum resistant ovarian cancer by end of 2023 New pre-clinical data presented at CIMT for COM503, a high affinity anti-IL-18BP antibody approach differentiated from cytokine therapeutic approaches Cash balance of $74.3 million with runway through potential key milestones expected into at least... Read More

HOLON, Israel , May 11, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will host a virtual DNAM-1 Axis Investor Event on Tuesday, May 23, 2023 at 12:00 pm ET . The event will feature Drew Pardoll , M.D., Ph.D. , Professor of Oncology, Johns Hopkins University , and Chairman of... Read More

HOLON, Israel , May 9, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the JMP Securities Life Sciences Conference (virtually), on Tuesday, May 16, 2023 at 9:00 AM ET . A live webcast of the presentation will be available on the Investor Relations section of Compugen's... Read More

HOLON, Israel , May 1, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2023 financial results on Monday, May 15, 2023 , before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a... Read More

HOLON, Israel , April 27, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 in triple combination with BMS-986207 (anti-TIGIT) and nivolumab in metastatic endometrial cancer at the American Society of Clinical Oncology (ASCO) annual meeting on June 2-6,... Read More

COM503 a potential first-in-class, high affinity anti- IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Compugen plans to file COM503 IND in 2024 HOLON, Israel , April 26, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present pre-clinical data on its lead... Read More

HOLON, ISRAEL , March 8, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference (virtual), on Wednesday, March 15, 2023 at 10:00 AM ET . A live webcast of the fireside chat will be available on the... Read More

Study builds on clinical benefit reported in heavily pretreated MSS CRC patients with liver metastases treated with dual combination of COM701 and nivolumab Initial findings expected by the end of 2023 HOLON, Israel , March 6, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the first patient has been dosed... Read More

On track to dose the first patients in MSS CRC and PROC triple combination proof of concept studies in Q1 2023 and Q2 2023, respectively, with the combination of potential first-in-class anti-PVRIG, COM701, potential best-in-class anti-TIGIT, COM902 and pembrolizumab Initial findings from both triple combination studies expected by end of 2023 Approximately $83.7 million in cash, as of end of 2022, expected to fund... Read More

Phase 3 study with rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq:AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902 is expected to start in 2023. AstraZeneca continues to expand rilvegostomig's Phase 2 development across multiple indications and combinations COM902, Compugen's potential best in class high affinity anti-TIGIT antibody was licensed in 2018 to AstraZeneca for exclusive use in bi-specific and... Read More

HOLON, Israel , Feb. 13, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, February 27, 2023 , before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide... Read More

HOLON, Israel , Feb. 9, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the SVB Securities Global Biopharma Conference (virtual), on Thursday, February 16, 2023 at 9:20 AM ET . A live webcast of the presentation will be available on the Investor Relations section of Compugen's... Read More

At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 (anti-TIGIT) demonstrated encouraging 20% overall response rate and 40% disease control rate in heavily pretreated patients with platinum resistant ovarian cancer and was well tolerated, with all responders remaining on therapy Longer follow up data will be included in the posters available on ESMO Immuno-Oncology Congress 2022 (ESMO-IO) virtual platform on... Read More

HOLON, Israel , Nov. 29, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat Cohen-Dayag , Ph.D., President and CEO, and additional members of its management team will participate in a virtual fireside chat at the upcoming JMP Securities Hematology and Oncology Summit. The fireside chat will take place on... Read More